Loomis Sayles & Co. L P cut its position in DexCom, Inc. (NASDAQ:DXCM) by 1.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,756 shares of the medical device company’s stock after selling 1,429 shares during the period. Loomis Sayles & Co. L P owned about 0.09% of DexCom worth $6,334,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. FMR LLC increased its stake in DexCom by 9.1% in the first quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock worth $834,201,000 after buying an additional 823,406 shares during the last quarter. Baillie Gifford & Co. increased its stake in DexCom by 1.4% in the first quarter. Baillie Gifford & Co. now owns 6,212,889 shares of the medical device company’s stock worth $526,418,000 after buying an additional 84,085 shares during the last quarter. Bank of New York Mellon Corp increased its stake in DexCom by 304.3% in the first quarter. Bank of New York Mellon Corp now owns 2,546,729 shares of the medical device company’s stock worth $215,785,000 after buying an additional 1,916,759 shares during the last quarter. Jennison Associates LLC increased its stake in DexCom by 2.1% in the first quarter. Jennison Associates LLC now owns 1,497,129 shares of the medical device company’s stock worth $126,852,000 after buying an additional 31,082 shares during the last quarter. Finally, State Street Corp increased its stake in DexCom by 39.7% in the fourth quarter. State Street Corp now owns 1,483,951 shares of the medical device company’s stock worth $88,624,000 after buying an additional 421,903 shares during the last quarter.
Shares of DexCom, Inc. (NASDAQ:DXCM) traded up 0.40% on Tuesday, reaching $78.27. 468,119 shares of the company were exchanged. The stock’s market capitalization is $6.76 billion. DexCom, Inc. has a 12 month low of $57.68 and a 12 month high of $96.38. The stock has a 50 day moving average price of $71.39 and a 200-day moving average price of $74.08.
DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.06. The firm had revenue of $142.30 million for the quarter, compared to the consensus estimate of $143.94 million. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%. On average, equities analysts expect that DexCom, Inc. will post ($0.70) EPS for the current fiscal year.
WARNING: This article was published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thestockobserver.com/2017/06/20/loomis-sayles-co-l-p-reduces-stake-in-dexcom-inc-dxcm.html.
DXCM has been the topic of a number of research reports. B. Riley reiterated a “buy” rating and issued a $95.00 target price on shares of DexCom in a report on Thursday, April 27th. Oppenheimer Holdings, Inc. set a $98.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Wednesday, March 1st. BidaskClub upgraded shares of DexCom from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Northcoast Research restated a “buy” rating on shares of DexCom in a report on Wednesday, March 1st. Finally, BTIG Research lowered shares of DexCom from a “buy” rating to a “neutral” rating in a report on Wednesday, May 3rd. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $90.44.
In other DexCom news, EVP Richard Doubleday sold 3,182 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $76.38, for a total transaction of $243,041.16. Following the sale, the executive vice president now directly owns 97,815 shares in the company, valued at approximately $7,471,109.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 8,649 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total transaction of $591,505.11. Following the sale, the chief executive officer now owns 347,329 shares in the company, valued at $23,753,830.31. The disclosure for this sale can be found here. Insiders have sold a total of 60,795 shares of company stock worth $4,428,513 over the last 90 days. Corporate insiders own 1.70% of the company’s stock.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.